Search Results 61-70 of 15422 for infliximab

  1. IBS Archives - Mayo Clinic News Network

    Dr. Picco recommended Marissa undergo treatment with the medication infliximab ... infliximab the following week, and she saw immediate results. "I went from ...

  2. Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease - Mayo Clinic

    Signs and symptoms of persistently active disease despite a history of at least 1 induction regimen of infliximab 5 mg/kg IV at Week 0 and Weeks 2 and 6 or ...

  3. A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants with Moderately to Severely Active Crohn's Disease (CD) - Mayo Clinic

    Initially responded to induction therapy with infliximab (≥ 5 mg/kg) or ... Infliximab. Any prior treatment with ustekinumab within 14 weeks prior to ...

  4. Bacillus of calmette and guerin vaccine, live (intravesical route) - Side effects & dosage - Mayo Clinic

    Infliximab; Ixekizumab; Lebrikizumab-lbkz; Leniolisib; Lovotibeglogene Autotemcel; Mirikizumab-mrkz; Mycophenolate Mofetil; Mycophenolic Acid. Show More. Using ...

  5. A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment - Mayo Clinic

    Demonstrated intolerance or inadequate response to one or more of the following biologic agents as defined below: infliximab, adalimumab, certolizumab pegol, ...

  6. A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) - Mayo Clinic

    ... infliximab; Intolerance to at least 2 anti-TNF-alpha biologic ... Has received infliximab, infliximab biosimilar, or golimumab intravenous (IV) ...

  7. Vedolizumab (intravenous route, subcutaneous route) - Side effects & dosage - Mayo Clinic

    Infliximab; Natalizumab. Other Interactions. Certain medicines should not be used at or around the time of eating food or eating certain types of food since ...

  8. A Study to Evaluate the Safety and Effectiveness of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease - Mayo Clinic

    At least one 6-week induction regimen of infliximab (≥5 mg/kg IV at Weeks 0 ... Approved biologics: infliximab, adalimumab, certolizumab, vedolizumab ...

  9. Ustekinumab-aauz (intravenous route, subcutaneous route) - Mayo Clinic

    Infliximab; Influenza Virus Vaccine, Live; Measles Virus Vaccine, Live; Mumps Virus Vaccine, Live; Poliovirus Vaccine, Live; Rotavirus Vaccine, Live; Rubella ...

  10. Publications - Melissa R. Snyder, Ph.D. - Mayo Clinic

    ... Infliximab and Adalimumab Without Acid Dissociation. ... Comparison of Clinical Laboratory Assays for Measuring Serum Infliximab and Antibodies to Infliximab.